Title: Paul R
Leonid:
Thank you very much for your clear and helpful answer.
May I suggest that the Weibull distribution function might be more clearly written:
B= IVIVC*PAR1 
WDER=(GAMA1/B)*((T/B)**(GAMA1-1))*EXP(-(T/B)**GAMA1)

Be well.
Paul

Leonid Gibiansky wrote:
Paul,
No, this is not a correct way to introduce drug to depot. The idea was:

Step 1. Fit Weibull or something similar to the dissolution data:
 time               t = 0, 1, 2,...
 fraction absorbed: f = 0, 0.1, 0.5 ..
Use model:
 f(t)=1-exp(t/to)^gamma
Using observed dissolution data, finds t0 and gamma that would provide good fit of the dissolution data
If needed, add extra parameter
  f(t)=A*(1-exp(t/to)^gamma)

Step 2: Assume some IVIVC model, for example:
 in-vivo dissolution is the same as in vitro:
  FF=1-exp(t/to)^gamma
or
  in-vivo dissolution is faster/slower then in vitro:
  FF=1-exp(t/(THETA(IVIVC)*t0))^gamma
 where THETA is estimated
or some other model

Step 3:
put drug to depot, but it should be in the $DES block, and it should be a derivative of FF, not FF itself:

$DES
 B=THETA(IVIVC)*t0
 WDER=GAMM/(B**GAMM))*T**(GAMM-1)*EXP(-(T/B)**GAMM)

 DADT(1)=F1*DOSE*WDER-KA*A(1)

Here t0 and GAMM are fixed (from in-vitro data fit) while THETA(IVIVC) corresponds to IVIVC and need to be estimated from the data.

If you would like to stop dissolution at some time TMAX, you can use:

$DES
 B=THETA(IVIVC)*t0
 WDER=GAMM/(B**GAMM))*T**(GAMM-1)*EXP(-(T/B)**GAMM)
 IF(T.GT.TMAX) WDER=0
 DADT(1)=F1*DOSE*WDER-KA*A(1)

If you would like to stop absorption at some time TMAX, you can use:
$DES
 B=THETA()*t0
 WDER=GAMM/(B**GAMM))*T**(GAMM-1)*EXP(-(T/B)**GAMM)
 IF(T.GT.TMAX) KA=0
 DADT(1)=F1*DOSE*WDER-KA*A(1)


Thanks
Leonid

--------------------------------------
Leonid Gibiansky, Ph.D.
President, QuantPharm LLC
web:    www.quantpharm.com
e-mail: LGibiansky at quantpharm.com
tel:    (301) 767 5566




Paul Hutson wrote:
Leonid & Jeroen:
Thank you for your suggestions.  I incorporated Jeroen's suggestion of using MTIME below, with a slight modification (KA = TVKA *(1-MPAST(1))), since I want to turn KA off, not on, at TOFF.

I try below to use Leonid's suggestion of a Weibull distribution to describe the dissolution of the oral product, rather than using multiple AMT & RATE inputs corresponding to the dissolution data for the product.  My fit deteriorates both by OBj Func and VPC.  Does the code below appear to be appropriate for introducing the oral drug in A(1) using a Weibull distribution?
Thanks very much
Paul

$SUBROUTINES ADVAN6 TOL=3
$MODEL COMP=(DEPOT, DEFDOSE) COMP=(CENTRAL, DEFOBS)
$PK
callfl=-2
CL=THETA(1)*EXP(ETA(1)); CLEARANCE
V2=THETA(2)*EXP(ETA(2)); V2
TOFF=THETA(3)*EXP(ETA(3)); DURATION OF PRESENCE IN ABSORPTION SEGMENT
K=CL/V2
AUC=AMT/CL
S2=V2/1000

;CLOSE ABSORPTION AFTER SOME TIME TOFF
TVKA=THETA(4)*EXP(ETA(4))
MTIME(1)=TOFF
KA=TVKA*(1.001-MPAST(1)); MPAST(1) = O UNTIL MTIME(1)(TOFF) IS REACHED, THEN IS 1

;DRUG APPEARANCE
PAR1=THETA(5); SCALING CONSTANT FOR TIME
GAMA1=THETA(6); SLOPE FUNCTION FOR WEIBULL
WB1=1-EXP(-((TIME/PAR1)**GAMA1))
RAT1 = AMT*WB1

$DES
DADT(1) = RAT1 - A(1)*KA
DADT(2) = A(1)*KA - A(2)*CL/V2

$ERROR
IPRE = F
W1=F
   DEL   = 0
   IF(IPRE.LT.0.001) DEL = 1
   IRES  = DV-IPRE;  NEGATIVE TREND IS OVERESTIMATING IPRED WRT DV
   IWRE = IRES/(W1+DEL)
Y=F*(1+ERR(1))+ERR(2)


$THETA  (0.1,1.23, 50);      CL
$THETA  (0.10,97.8,1000);    V2
$THETA  (0.1,86.5,1000);      TOFF
$THETA  (0.0001, .7, 4); KA
$THETA  176.1 FIXED; PAR1
$THETA    1.033 FIXED ; SLOPE

 
$OMEGA   0.5; CL
$OMEGA   0.3; V2
$OMEGA   0.6; TOFF
$OMEGA   0.3; ka


$SIGMA  .5;         SIG1
$SIGMA  .1;         SIG2

$ESTIMATION METH=1 INT SIGDIGITS=3 MAXEVAL=9999 PRINT=10 NOABORT

Elassaiss - Schaap, J. (Jeroen) wrote:
Leonid, Paul,

Alternatively one may use the MTIME function in NM6 so the algebraic
solutions in eg. ADVAN2 are still applicable:

$PK
....
MTIME(1)=TOFF
KA=TVKA*MPAST(1)

Best regards,
Jeroen

Jeroen Elassaiss-Schaap, PhD
Modeling & Simulation Expert
Pharmacokinetics, Pharmacodynamics & Pharmacometrics (P3)
Early Clinical Research and Experimental Medicine
Schering-Plough Research Institute
T: +31 41266 9320


-----Original Message-----
From: [email protected] [mailto:[email protected]]
On Behalf Of Leonid Gibiansky
Sent: Friday, 11 December, 2009 6:55
To: [email protected]
Cc: [email protected]
Subject: Re: [NMusers] Duration of Absorption Time From Depot (Gut) as
Covariate

Paul,
You need to rewrite the system using differential equations rather than
ADVAN2 and then use

$DES
FLAG=1
IF(T.GE.TOFF) FLAG=0.0001
KA=TVKA*FLAG

In the PK block, this should not work because your TIME is discrete
while nonmem is trying small variation of TOFF parameter to compute the
gradient (which is indeed zero if you do it in the PK block)

On a different note, you are assuming 1 to 1 IVIVC (in-vitro dissolution
= in vivo dissolution). It is rarely the case. You may try to describe
your dissolution profile by some function (Weibull is very flexible) and
then use parametric _expression_ for IVIVC (for example, time scaling) to
insert the dose into the depot compartment (as input rate)

Thanks
Leonid



--------------------------------------
Leonid Gibiansky, Ph.D.
President, QuantPharm LLC
web:    www.quantpharm.com
e-mail: LGibiansky at quantpharm.com
tel:    (301) 767 5566




Paul Hutson wrote:
 
I have been asked to look at data that suggest a dependence of AUC and
   

 
Cmax upon transit time in the gut.  The elimination rates for the one compartment model are quite similar, suggesting that the variability lies in bioavailability.  Preliminary data suggest that the absorption
   

 
of this drug from the gut is transporter-limited, and may be dependent
   

 
upon the duration of time that the drug is exposed to a specific portion of the duodenum or jejunum.  Drug is observed at the earliest sampling time, so I am not including a Tlag at this point.

I have in vitro dissolution data for this (hopefully) extended release
   

 
formulation, which I am introducing to the gut compartment for the human subject PK data as events of AMT and RATE corresponding to each measured point in the dissolution curve.  Thus I am fixing it as a time-dependent inputs over the 12 hour period following the single dose and during the plasma sampling.  Because of the non-instantaneous
   

 
input function, I understand I cannot use Savik's TRANSIT model
   
(2007).
 
I have tried the code below to try to turn off Ka after some time TOFF, the point at which the drug is estimated to have moved past the section of absorption.  There is no change in the gradient for TOFF, and the fit is not improved over a simple 1 compartment absorption
   
model (ADVAN2).
 
I cannot turn off compartment 1 (-1) in my INPUT, since I do not know when to turn it off (I am trying to determine this in the model).   There is extensive first pass of the compound - I do not know of any auto-inhibition of metabolism.  I suppose that I could try to trip F1 to null at some TOFF, but tripping Ka to Null seems more physiologic.

Can anyone suggest a snippet of code that might close Ka based upon a covariate THETA corresponding to the time required to move past the intestinal segment of absorption?
Thanks very much.
Paul

$SUBROUTINES ADVAN2
; 1 COMPARTMENT MODEL, NO LAG, NO LIMIT TO ABSORPTION PERIOD


$PK
TVKA=THETA(1); ABSORPTION RATE FROM GUT CL=THETA(2)*EXP(ETA(1)); CLEARANCE V2=THETA(3)*EXP(ETA(2)); V2 TOFF=THETA(4)*EXP(ETA(3)); DURATION OF PRESENCE IN ABSORPTION SEGMENT
K=CL/V2
DOSE=5; MG TABLET
AUC=DOSE/CL
S2=V2/1000

FLAG=1
IF(TIME.GE.TOFF) FLAG=0.0001
KA=TVKA*FLAG

$ERROR
IPRE = F
W1=F
   DEL   = 0
   IF(IPRE.LT.0.001) DEL = 1
   IRES  = DV-IPRE;  NEGATIVE TREND IS OVERESTIMATING IPRED WRT DV
   IWRE = IRES/(W1+DEL)
Y=F*(1+ERR(1))+ERR(2)


$THETA  (0.1,1.23, 50);      KAGUT
$THETA  (0.10,97.8,1000);      CL
$THETA  (0.1,86.5,1000);      V2
$THETA  (0.001, 1, 24); DUR


;$OMEGA   0.3; KA
$OMEGA   0.5; CL
$OMEGA   0.3; V2
$OMEGA   0.6; TOFF
--

Paul R. Hutson, Pharm.D.

Associate Professor

UW School of Pharmacy

777 Highland Avenue

Madison WI 53705-2222

Tel  608.263.2496

Fax 608.265.5421

Pager 608.265.7000, p7856

   


This message and any attachments are solely for the intended recipient. If you are not the intended recipient, disclosure, copying, use or distribution of the information included in this message is prohibited --- Please immediately and permanently delete.
 

-- 

Paul R. Hutson, Pharm.D.

Associate Professor

UW School of Pharmacy

777 Highland Avenue

Madison WI 53705-2222

Tel  608.263.2496

Fax 608.265.5421

Pager 608.265.7000, p7856


--

Paul R. Hutson, Pharm.D.

Associate Professor

UW School of Pharmacy

777 Highland Avenue

Madison WI 53705-2222

Tel  608.263.2496

Fax 608.265.5421

Pager 608.265.7000, p7856

Reply via email to